Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin Solomon, Tony Mok, Todd M. Bauer et al.|Journal of Clinical Oncology|2022Cited by 133
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel W. Neal, Thomas Newsom-Davis, Nick Pavlakis et al.|Journal of Clinical Oncology|2024Cited by 57
Contents &middot; Inhalt Vol. 32, Issue 6, 2009Ernesto Zanet, Zdeněk Adam, Alessandra Bearz et al.|Onkologie|2009Cited by 0